Skip to main content
Erschienen in: Journal of Nuclear Cardiology 2/2019

01.04.2019 | Editorial

Nuclear imaging of cardiac amyloidosis

verfasst von: Efstathia Andrikopoulou, MD, Pradeep Bhambhvani, MD

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Excerpt

Amyloidosis is a multi-system disorder affecting various organs and histologically defined by deposition of abnormal proteins (amyloid fibrils) with characteristic staining pattern. Cardiac involvement may be seen with AL amyloidosis, characterized by deposition of light chains, and TTR amyloidosis, characterized by deposition of transthyretin, either genetically abnormal (mutant transthyretin, familial form of cardiac amyloidosis) or normal (wild-type transthyretin-wt, senile systemic amyloidosis). Cardiac amyloidosis (CA) is an underdiagnosed clinical entity affecting 50% of the patients with AL amyloidosis, in almost all patients with wt-TTR amyloidosis and with variable frequency of cardiac involvement in mutant-TTR amyloidosis depending on the underlying mutation.1,2 Under-diagnosis is partly due to the inherent difficulty in making a definitive diagnosis of CA, for which endomyocardial biopsy remains the gold standard. Tissue-based diagnosis, however, is an invasive approach and it is not uncommon for patients either to be considered too high of a risk to undergo biopsy, or refuse biopsy. In these cases, diagnosis of CA relies on (a) obtaining tissue from a different site (abdominal fat pad, salivary glands etc.) and (b) identifying signs indicative of CA on cardiac magnetic resonance imaging. Another reason why diagnosis of CA is challenging is because its cardinal echocardiographic features (increased ventricular wall thickness, impaired diastolic function) are also frequently seen with other common disorders, most notably hypertensive heart disease and other restrictive cardiomyopathies. …
Literatur
1.
Zurück zum Zitat Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.PubMed Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.PubMed
2.
Zurück zum Zitat Bravo PE, Dorbala S. Targeted nuclear imaging probes for cardiac amyloidosis. Curr Cardiol Rep 2017;19:59.CrossRefPubMed Bravo PE, Dorbala S. Targeted nuclear imaging probes for cardiac amyloidosis. Curr Cardiol Rep 2017;19:59.CrossRefPubMed
3.
Zurück zum Zitat Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-7.CrossRef Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-7.CrossRef
4.
Zurück zum Zitat Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: A comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425-9.CrossRefPubMed Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: A comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425-9.CrossRefPubMed
5.
Zurück zum Zitat Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007;110:3561-3.CrossRefPubMedPubMedCentral Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007;110:3561-3.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 2012;119:1117-22.CrossRefPubMedPubMedCentral Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 2012;119:1117-22.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84.CrossRefPubMed Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84.CrossRefPubMed
9.
Zurück zum Zitat Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659-70.CrossRef Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659-70.CrossRef
10.
Zurück zum Zitat Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38:470-8.CrossRefPubMed Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38:470-8.CrossRefPubMed
11.
Zurück zum Zitat Kristen AV, Scherer K, Buss S, aus dem Siepen F, Haufe S, Bauer R, et al. Noninvasive risk stratification of patients with transthyretin amyloidosis. JACC Cardiovasc Imaging 2014;7:502-10.CrossRefPubMed Kristen AV, Scherer K, Buss S, aus dem Siepen F, Haufe S, Bauer R, et al. Noninvasive risk stratification of patients with transthyretin amyloidosis. JACC Cardiovasc Imaging 2014;7:502-10.CrossRefPubMed
12.
Zurück zum Zitat Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging 2014;15:1289-98.CrossRefPubMed Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging 2014;15:1289-98.CrossRefPubMed
13.
Zurück zum Zitat Glaudemans AW, van Rheenen RW, van den Berg MP, Noordzij W, Koole M, Blokzijl H, et al. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid 2014;21:35-44.CrossRefPubMed Glaudemans AW, van Rheenen RW, van den Berg MP, Noordzij W, Koole M, Blokzijl H, et al. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid 2014;21:35-44.CrossRefPubMed
14.
Zurück zum Zitat Galat A, Rosso J, Guellich A, van der Gucht A, Rappeneau S, Bodez D, et al. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid 2015;22:210-20.CrossRefPubMed Galat A, Rosso J, Guellich A, van der Gucht A, Rappeneau S, Bodez D, et al. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid 2015;22:210-20.CrossRefPubMed
15.
Zurück zum Zitat Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: Predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 2016;1(8):880-9.CrossRefPubMed Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: Predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 2016;1(8):880-9.CrossRefPubMed
16.
Zurück zum Zitat Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195-201.CrossRefPubMedPubMedCentral Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195-201.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.CrossRef Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.CrossRef
18.
Zurück zum Zitat Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: Implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol 2016;25:413-7.CrossRef Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: Implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol 2016;25:413-7.CrossRef
19.
Zurück zum Zitat Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjö L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nuclear Med 2013;54:213-20.CrossRef Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjö L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nuclear Med 2013;54:213-20.CrossRef
20.
Zurück zum Zitat Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR, Di Carli MF, et al. Imaging cardiac amyloidosis: A pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 2014;41:1652-62.CrossRef Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR, Di Carli MF, et al. Imaging cardiac amyloidosis: A pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 2014;41:1652-62.CrossRef
21.
Zurück zum Zitat Cappelli F, Gallini C, Di Mario C, Costanzo EN, Vaggelli L, Tutino F, et al. Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. J Nucl Cardiol 2017. doi:10.1007/s12350-017-0922-z.CrossRefPubMed Cappelli F, Gallini C, Di Mario C, Costanzo EN, Vaggelli L, Tutino F, et al. Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. J Nucl Cardiol 2017. doi:10.​1007/​s12350-017-0922-z.CrossRefPubMed
22.
Zurück zum Zitat Osborne DR, Acuff SN, Stuckey A, Wall JS. A Routine PET/CT Protocol with streamlined calculations for assessing cardiac amyloidosis Using (18)F-florbetapir. Front Cardiovasc Med 2015;2:23.CrossRefPubMedPubMedCentral Osborne DR, Acuff SN, Stuckey A, Wall JS. A Routine PET/CT Protocol with streamlined calculations for assessing cardiac amyloidosis Using (18)F-florbetapir. Front Cardiovasc Med 2015;2:23.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Law WP, Wang WY, Moore PT, Mollee PN, Ng AC. Cardiac amyloid imaging with 18F-florbetaben PET: A pilot study. J Nucl Med 2016;57:1733-9.CrossRef Law WP, Wang WY, Moore PT, Mollee PN, Ng AC. Cardiac amyloid imaging with 18F-florbetaben PET: A pilot study. J Nucl Med 2016;57:1733-9.CrossRef
Metadaten
Titel
Nuclear imaging of cardiac amyloidosis
verfasst von
Efstathia Andrikopoulou, MD
Pradeep Bhambhvani, MD
Publikationsdatum
01.04.2019
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 2/2019
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-017-1028-3

Weitere Artikel der Ausgabe 2/2019

Journal of Nuclear Cardiology 2/2019 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.